Head-to-head · Cost-Efficiency Index
LunaRx vs Wisp
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
LunaRx
Shoppers who value simple flat-rate pricing and a no-cost-if-declined guarantee over named clinical credentials.
Visit LunaRxWisp
Cost-first shoppers who want branded injectables plus a sublingual semaglutide alternative.
Visit WispThe verdict
LunaRx and Wisp tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with LunaRx (ranked #197, a hair above #202) — Shoppers who value simple flat-rate pricing and a no-cost-if-declined guarantee over named clinical credentials. But Wisp is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs LunaRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | LunaRx | Wisp |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | $149/mo (compounded) | $225/mo (compounded oral) |
| Tirzepatide / mo | $199/mo (compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $1,788 | $2,700 |
| Tirzepatide / yr (modeled) | $2,388 | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #197 | #202 |
LunaRx
63/100Where the value is
- Advertises simple, flat-rate pricing with no hidden fees
- '$0 if not approved' removes financial risk from a declined consult
- Founder is publicly named (Anamaria Galvan, RN) rather than fully anonymous leadership
The tradeoffs
- No named physician medical director -- only an RN founder is identified
- No named compounding pharmacy partner
Wisp
63/100Where the value is
- Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
- LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
- Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary
The tradeoffs
- The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
- The compounded semaglutide option is sublingual drops, which Wisp itself describes as less effective than injection
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.